A case of successful use of cytokines in combination treatment of breast cancer: clinical case



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Treatment of HER2/neu-positive breast cancer presents significant challenges. Almost 50% of patients fail to achieve complete tumor regression using neoadjuvant antitumor therapy standards. It is important to search for new approaches to overcome the limitations of targeted therapy, reduce the side effects of antitumor treatment without losing its effectiveness. One such direction may be the use of cytokine gene therapy drugs — interferon gamma and a hybrid drug of recombinant tumor necrosis factor thymosin α1.

CLINICAL CASE DESCRIPTION: A patient with a histologically confirmed diagnosis of breast cancer cT2N3M0, stage III, non-luminal, HER2/neu positive (ER 0, PR 0, HER2/neu 3+, Ki67 70%) underwent 2 courses of treatment according to the paclitaxel, trastuzumab, pertuzumab regimen and consulted the clinic due to poor tolerability of the therapy. The patient, while continuing standard antitumor treatment, was prescribed cytokine gene therapy with interferon-gamma and recombinant tumor necrosis factor thymosin α1. After 2 courses of combination therapy, the patient noted an improvement in her quality of life. After the 8th course of treatment, complete regression of the tumor in the mammary gland, axillary and supraclavicular lymph nodes was achieved, confirmed by mammography, computed tomography and morphological examination of the removed breast tissue. An increase in TNFα and Karnofsky index was noted against the background of the treatment. Currently, the patient continues to receive maintenance courses of cytokinesigenetic therapy.

CONCLUSION: The inclusion of cytokine genetic therapy drugs in the neoadjuvant drug therapy improved the patient's quality of life, potentiated the effect of antitumor drugs and achieved complete tumor regression.

Full Text

Restricted Access

About the authors

Amir M. Ben Ammar

OncoCare Clinic 308, Moscow, Russia

Email: info@oncocareclinic.ru
ORCID iD: 0000-0001-9239-2539
Russian Federation, Moscow, Russia

Vladimir T. Zarkua

OncoCare Clinic 308, Moscow, Russia

Email: miro.zarkua@gmail.com
SPIN-code: 9383-8150
Russian Federation, Moscow, Russia

Andrey L. Ilyushin

OncoCare Clinic 308, Moscow, Russia

Author for correspondence.
Email: onkolog_77@mail.ru
ORCID iD: 0009-0000-5065-4342
SPIN-code: 8808-6761

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow, Russia

References

  1. Merabishvili VM, Semiglazov VF, Komyakhov AV, et al. The state of cancer care in Russia: breast cancer. Epidemiology and survival of patients. The impact of the SARS-CoV-2-beta-coronavirus epidemic (clinical and population study). Tumors of female reproductive system. 2023;19(3):16–24. doi: 10.17650/1994-4098-2023-19-3-16-24
  2. Krasniqi E, Barchiesi G, Pizzuti L, et al. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. J Hematol Oncol. 2019;12(111). doi: 10.1186/s13045-019-0798-2
  3. Liu R, Mao X, Li T, et al. Immunotherapy and immunоbiomarker in breast cancer: current practice and future perspectives. Am J Cancer Res. 2022;12(8):3532–3547
  4. Ilyushin AL, Ben Ammar AM. A case of successful treatment of pancreatic cancer. Russian Journal of Oncology. 2022;27(5):243–250. doi: 10.17816/onco456482
  5. Ardzha AYu, Nepomnyashchaya EM, Zlatnik EYu, et al. Features of the expression of some immunohistochemical markers in patients with stage IIIC-IV ovarian cancer as a criterion for the effectiveness of chemoimmunotherapy. Science of the Young. 2020;8(4):582–90. doi: 10.23888/HMJ202084582-590
  6. Costantini C, Bellet MM, Pariano M, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Sec. Cancer Immunity and Immunotherapy. 2019;9. doi: 10.3389/fonc.2019.00873
  7. Broglio KR, Quintana M, Foster M, et al. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncol. 2016;2(6):751–760. doi: 10.1001/jamaoncol.2015.6113
  8. Jia Y, Kodumudi KN, Ramamoorthi G, et al. Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. Molecular Therapy. 2021;29(4):1541–1556. doi: 10.1016/j.ymthe.2020.12.037
  9. Zhuang X, Shi G, Hu X, et al. Interferon-gamma inhibits aldehyde dehydrogenasebright cancer stem cells in the 4T1 mouse model of breast cancer. Chinese Medical Journal. 2022;135(2):194–204. doi: 10.1097/CM9.0000000000001558
  10. Gocher AM, Workman CJ, Vignali DAA. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22:158–172. doi: 10.1038/s41577-021-00566-3
  11. Fang C, Weng T, Hu S, et al. IFN-γ-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells. Oncoimmunology. 2021;10(1). doi: 10.1080/2162402X.2021.1962591
  12. Mojic M, Takeda K, Hayakawa Y. The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion. International Journal of Molecular Sciences. 2018;19(1):89. doi: 10.3390/ijms19010089
  13. Shen X, Li Q, Wang F, et al. Generation of a novel long-acting thymosin alpha1-Fc fusion protein and its efficacy for the inhibition of breast cancer in vivo. Biomedicine & Pharmacotherapy. 2018;108:610–617. doi: 10.1016/j.biopha.2018.09.064
  14. Vladimirova LYu, Podzorova NA, Zlatnik EYu, et al. Experience of peritumoral application of recombinant hybrid protein of tumor necrosis factor-alpha-thymosin-alpha1 in stage IIB-IIIB locally advanced breast cancer. Fundamental research. 2014;7:921–926. (In Russ.)

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 86496 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ЭЛ № ФС 77 - 80673 от 23.03.2021 г
.